国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2011年
2期
127-129
,共3页
乳腺肿瘤%DNA拓扑异构酶类%Ⅱ型%蒽环类
乳腺腫瘤%DNA拓撲異構酶類%Ⅱ型%蒽環類
유선종류%DNA탁복이구매류%Ⅱ형%은배류
Breast neoplasms%DNA topoisomerases,type Ⅱ%Anthracyclines
含蒽环类方案目前广泛应用于乳腺癌的治疗,其疗效与拓扑异构酶Ⅱ(TOP2)基因的异常状态存在关联,已有临床研究表明HER2基因扩增伴有TOP2基因异常的患者是蒽环类治疗的主要受益人群,但该结论未达成共识.
含蒽環類方案目前廣汎應用于乳腺癌的治療,其療效與拓撲異構酶Ⅱ(TOP2)基因的異常狀態存在關聯,已有臨床研究錶明HER2基因擴增伴有TOP2基因異常的患者是蒽環類治療的主要受益人群,但該結論未達成共識.
함은배류방안목전엄범응용우유선암적치료,기료효여탁복이구매Ⅱ(TOP2)기인적이상상태존재관련,이유림상연구표명HER2기인확증반유TOP2기인이상적환자시은배류치료적주요수익인군,단해결론미체성공식.
Anthracycline-based chemotherapeutic agents were extensively applied to the treatment of breast cancer. The relation of its response to TOP2A gene was proved by a number of clinical studies demonstrating that patients with both HER2 gene amplification and TOP2A gene aberration have a favored outcome,but a consensus was not yet achieved.
